AzTrials
AzTrials

ScabiesPhase 3NCT06396507

Sulfur vs. Different Regimes of Permethrin for Scabies

A Phase 3 study testing Permethrin Solution and Sulfur in people with Scabies, run by Damascus University at 3 sites in Syria.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Read more about this study

Who is it for?
Ages 2 years and older
Conditions the study is for
Scabies
What is being tested?
Permethrin Solution and Sulfur
Could I receive a placebo?
No, everyone receives an active treatment
How many people
250 participants
Where
3 sitesSyria
Study dates
15 Mar 2022to 12 Nov 2022
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Scabies participants who meet "The 2020 International Alliance for the Control of Scabies (IACS) Consensus Criteria" level A or B.
  • Participants can apply the treatment themselves or by their guardians if they are children.
  • Participants willing to commit to the study's requirements

Who cannot join

  • Participants are younger than two years.
  • Participants with other skin diseases that could interfere with their assessment.
  • Participants who received treatment for scabies in the preceding month.
  • Receiving treatment with corticosteroids in the preceding week.
  • Pregnancy, planning for pregnancy during the study, or breastfeeding.
  • Systemic infection or receiving systemic therapy for an infectious disease
Show all 12Show fewer
  • Immunocompromised Participants.
  • Participants with crusted/Norwegian scabies.
  • Having sensitivity or allergy to permethrin or sulfur.
  • Participants with abnormal liver and kidney functions, thyroid disease, cardiac disorders, psychiatric illnesses.
  • Participation of a family member, or another member of the household in the current study.
  • The number of participants' households is seven or more.

Trial locations and contacts

3 sites in 1 country.

Syria3 sites
  • University of Aleppo

    Aleppo, 15310

  • Faculty of Medicine, University of Damascus

    Damascus, DM20AM19

  • University of Tishreen

    Latakia, 00000

Other trials in Syria

About this study

Official title: Comparing Sulfur to Different Regimes of Permethrin for the Treatment of Scabies

In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.

Read the detailed description

Background:

In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease that affects more than 200 million people at any time. Treating scabies in developing countries constitutes a major challenge because of factors like poverty, overcrowded areas, inadequate disease education, and low adherence to proper therapy, which together can contribute to treatment failure and the spread of the disease.

These factors abundantly exist in Syria as it is considered a developing, low-income country. Moreover, the long-term Syrian war added a significant negative impact to the socio-economic status and prevalence of scabies, raising the difficulty in controlling the disease.

Several treatment options may be used for classic scabies including permethrin 5%, crotamiton 10%, sulfur (5-10%) ointment, lindane 1%, and ivermectin. There is no ideal scabicide because the treatment choice changes according to the patient's situation, and any one of the previous agents may be used alone or in combination.

Permethrin 5% lotion or cream is the treatment of choice for scabies based on a 2007 updated Cochrane review. Most of the treatment guidelines in developing countries recommend applying the drug once a week for 8-14 hours and repeating the application after seven days. According to what is published in the medical literature, this regimen of permethrin application is usually effective and sufficient without significant drug resistance yet.

Sulfur is an old preparation for scabies treatment. It is usually used as a (5-10%) precipitated ointment over the whole body for two or three consecutive nights.

Unlike most scabicides, sulfur is effective in killing both the mites and the eggs. However, it is malodorous, cloth-spotting, and can cause irritant dermatitis. Despite the little clear scientific evidence on the clinical efficacy of sulfur and the low adherence to this treatment because of its unpleasant application effects, it is still used when the patient cannot tolerate other agents. Moreover, it is considered a safe choice in treating pregnant women and children, and it can be the only feasible scabicide in poor resources communities.

Although the evidence on repeated treatment (i.e., timing and frequency) is lacking, the majority of Syrian dermatology practitioners do not follow the classical regimen in prescribing permethrin with no specific and clear fact-based explanation of this variation. Based on a nationwide survey study the investigators conducted, 66% (105/159) of the Syrian dermatology practitioners tend to use more aggressive regimens in prescribing permethrin instead of the classic one-per-week recommended regimen.

The objective of the study:

To compare the efficacy of different regimens of permethrin application (i.e., varying in timing and frequency) to sulfur as a low-cost alternative. A secondary aim is to evaluate the adverse events and adherence.

Methods:

Participants and interventions It is a prospective, multi-center, randomized controlled trial that will be conducted at the dermatology departments of three academic hospitals run by the ministry of higher education in Syria; These hospitals are located in Damascus, Aleppo, and Latakia.

Diagnosis of scabies will be established based on the criteria of the International Alliance for the Control of Scabies (IACS 2020), which has three levels of certainty for diagnosing scabies; confirmed, clinical, and suspected scabies (Appendix A). Patients who fulfill the clinical or confirmed scabies items will be recruited. The investigators will examine the patient's skin looking for burrows, small papules, and vesicles which are the primary lesions of scabies, or the secondary lesions resulting from scratching and rubbing.

The severity of pruritus will be determined using the Verbal Rating Scale from zero (no itch) to four (very severe itch) (Appendix B). On the other hand, the severity of scabies will be measured by counting the number of lesions and grading the results as follows: score 0= Free of lesions (no scabies), score 1= 10 or fewer lesions (mild), score 2= 11- 49 lesions (moderate), score 3= 50 or more lesions (severe) (Appendix C).

Interventions:

All the participants will apply the medication in the same manner; the differences will be in the frequency of applications and showers between them. Directions of use for permethrin solution and sulfur ointment will be orally explained by the investigators to all participants with the help of figures specially designed for our study. The application of the solution will be to the whole body below the neck, including soles, between fingers and toe creases, in the folds of wrist and waistline, armpits, preauricular area, on the genitals, and beneath fingernails and toenails. Nails will be cut short, and sex will be avoided during treatment. If the patient is a child, hands and feet should be rubbed well. No supplementary treatment other than the prescribed anti-scapetic treatment is allowed during the study. Hygiene instructions are advised to be strictly followed to avoid recurrence and failure of treatment. Treatment was also instructed to all family members at the same time, including washing clothes and bedsheets at 60-celsius degrees. Clothes that cannot be washed will be put in a black plastic bag for 3 days, and vacuum cleaning will be instructed for house furniture.

The five arms of the study represent four different regimens of permethrin 5% solution application and a sulfur ointment group. The first arm (P1) will serve as the control group (i.e., active comparator), which is the standard regimen of permethrin application according to global guidelines (7). Patients on this arm will apply the 5% permethrin solution on day one, rinse it after eight hours and reapply it on day eight. Patients in group two (Arm P2) will apply the same solution on days one, two, and three then rinse it (without rinsing in between these days) and reapply it on days eight, nine, and ten then rinse it similarly to the first round. Participants in group three (Arm P3) will apply the solution on days one, two, and three then rinse it (without rinsing in between these days) and reapply it on day eight then rinse it. Participants in group four (Arm P4) will apply the solution on day one then rinse it, and on day two then rinse it. Later on day eight, they will re-apply the solution again and rinse it. Participants in group five (Arm S) will apply the ointment for three consecutive days without rinsing in between these days. Each application of the solution or the ointment is left for at least 8 hours (see figure 1 in Appendix D). Enough amounts of the previous antiscabetic medications will be distributed for free to all participants to ensure adherence and adequate and proper use of medication.

Participants who have a secondary infection will be treated with azithromycin capsules 500 mg for three consecutive days.

Participant timeline:

Participants will be assessed biweekly for at least 4 weeks starting with the day of the first application of the treatment. Participants who recovered at the "first visit" two weeks after applying the treatment will be re-evaluated at the "second visit" during the fourth week to check for recurrence. Participants who did not recover at the first visit will reapply the treatment of permethrin (according to their group regimen) as for the permethrin groups or reapply the sulfur (Arm S) as for the sulfur group. Then they will be re-evaluated at the "second visit" (week 4) and again at an additional "third visit" during week 6.

Patients who do not respond to the repeated treatment or experience recurrence (i.e., the reappearance of new lesions after complete recovery) will be treated with benzyl benzoate lotion as an alternative treatment (see figure 2 in Appendix D)

Assignment of interventions Participants will be randomly assigned to the five arms of the study using a web-based random number generator (randomlists.com). Investigators in each center will allocate the participants to the proper group and give the instructions and medications to them.

No blinding will be applied due to the different regimens of applying the medication in the permethrin groups and the different pharmaceutical properties of permethrin and sulfur.

Data collection, management, and analysis

Data collection methods:

After confirming the diagnosis according to the diagnosis criteria, data will be collected by the investigators directly from the participants, In addition to the demographic data, the structured questionnaire includes the history of the complaint, presence of secondary infection, number of family members, and the severity of itching. The follow-up questionnaire is more concise and it assesses treatment outcomes and the compliance of patients and their contacts to the instructions, in addition to the assessment of the medication side effects.

Collected data will be written on a paper form then entered into an electronic form, which will be reviewed and double-checked by the principal investigator. Photos will be taken using a mobile camera before treatment and on each visit to allow visual comparison.

Statistical methods:

Counts and percentages will be used for nominal variables. Medians and interquartile ranges will represent the continuous variables. Chi-square test will be used to study the association between categorical variables and Kruskal Wallis for continuous data. The analysis will be done using SPSS 25 software primarily, along with figures illustrated using Microsoft EXCEL.

APPENDIX A: International Alliance for the Control of Scabies (IACS 2020) A.confirmed scabies

At least one of:

A1: Mites, eggs, or faeces on light microscopy of skin samples A2: Mites, eggs, or faeces visualized on an individual using a high-powered imaging device A3: Mite visualized on an individual using dermoscopy

  1. Clinical scabies

At least one of:

B1: Scabies burrows B2: Typical lesions affecting male genitalia B3: Typical lesions in a typical distribution and two history features H1: Itch H2: Positive contact history

  1. Suspected scabies

One of:

C1: Typical lesions in a typical distribution and one history feature C2: Atypical lesions or atypical distribution and two history features History features

APPENDIX B: Verbal rating scale of pruritus 0 = No itch

  1. = Mild itching
  2. = Moderate itching
  3. = Severe itching
  4. = Very severe itching

APPENDIX C: Rating the lesions count Score 0 = no scabies Score 1 = lesions are 10 or less /mild/ Score 2 = lesions are between 11 - 49 /moderate/ Score 3 = lesions are 50 or more /severe/

Conditions
Scabies
Being tested
Permethrin Solution, Sulfur
Keywords
Scabies, Permethrin, Sulfur, Skin Diseases, Parasitic Diseases, Sarcoptes scabiei, scabies mite, Skin Infectious Diseases
Medical subject headings
Scabies, Skin Diseases, Parasitic Diseases, Skin Diseases, Infectious

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Permethrin SolutionDrug

    Also called Primothrin®, Permethrin®, Cidal®

    permethrin 5 % solution

  • SulfurDrug

    Also called sulphur

    Sulfur 10%+ vaseline 90 % ointment

Study groups in NCT06396507
Study groupRoleWhat they receive
Arm P1Active comparatorPermethrin 5% solution Participants randomly assigned to this group will apply the solution once, leave it on for ≥ 8 hours, rinse it, then reapply it the same way on day 8.
Receives: Drug: Permethrin Solution
Arm P2ExperimentalPermethrin 5% solution Participants randomly assigned to this group will apply the solution on days one, two, and three -for ≥ 8 hours each day- then rinse it (without rinsing in between these days) and reapply it on days eight, nine, and ten then rinse it.
Receives: Drug: Permethrin Solution
Arm P3ExperimentalPermethrin 5% solution Participants randomly assigned to this group will apply the solution on days one, two, and three -for ≥ 8 hours each day- then rinse it (without rinsing in between these days). They will reapply it on day eight and rinse it after ≥ 8 hours.
Receives: Drug: Permethrin Solution
Arm P4ExperimentalPermethrin 5% solution Participants assigned to this group will apply the solution on the first two days in the first week (for ≥ 8 hours each day with rinsing in between these days) and reapply it on day eight and rinse it after ≥ 8 hours.
Receives: Drug: Permethrin Solution
Arm SExperimentalSulfur 10%+ vaseline 90 % ointment Participants assigned to this group will apply the ointment for three consecutive days (for ≥ 8 hours each day and without rinsing in between these days).
Receives: Drug: Sulfur

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical Recovery

    Clinical recovery is defined as:

    • Absence of new scabietic skin lesions, AND
    • All remaining scabietic lesions are in healing, AND
    • Improvement of itch, defined by a decrease in itching grading score up to grade 0, 1, or 2 or a decrease for one grade, as for the participants who were diagnosed as grade 2 or less from the first visit.

    The variable is binary: Yes or No.

    Measured: At day 14 and 28 following the intervention.

Secondary outcomes (2)
  1. Rate of adverse events

    • Stinging (Stinging sensation after the application of the drug)
    • Erythema (any erythematous lesion that appears after the application of the drug)
    • Rash (any localized or general rash that appears after the application of the drug)
    • Itching (exaggerating of itch after the application of the drug)
    • Any other unexpected adverse events

    Measured: At day 14 and 28 following the intervention.

  2. Verbal rating scale of pruritus

    0 = No itch, 1= Mild itching, 2= Moderate itching, 3= Severe itching, 4= Very severe itching.

    Measured: At day 14 and 28 following the intervention.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 May 2024
  2. Study start15 Mar 2022
  3. Primary completion15 Sep 2022
  4. Study completion12 Nov 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be randomly assigned to one of the five groups (Permethrin 5% P1, P2, P3, P4, and sulfur S). Participants will be followed every two weeks for a month to evaluate primary and secondary outcomes.
Masking
None (open label)
Enrolment
250 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06396507
Sponsor's protocol ID
UDMS-Dermatology-06-2022
Status last verified
May 2024
First submitted
15 Feb 2023
Last updated
2 May 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Walton SF, Currie BJ. Problems in diagnosing scabies, a global disease in human and animal populations. Clin Microbiol Rev. 2007 Apr;20(2):268-79. doi: 10.1128/CMR.00042-06.

    PubMed 17428886
  • Hay RJ, Steer AC, Engelman D, Walton S. Scabies in the developing world--its prevalence, complications, and management. Clin Microbiol Infect. 2012 Apr;18(4):313-23. doi: 10.1111/j.1469-0691.2012.03798.x.

    PubMed 22429456
  • Fuller LC. Epidemiology of scabies. Curr Opin Infect Dis. 2013 Apr;26(2):123-6. doi: 10.1097/QCO.0b013e32835eb851.

    PubMed 23411418
  • Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD000320. doi: 10.1002/14651858.CD000320.pub2.

    PubMed 17636630
  • Khalil S, Abbas O, Kibbi AG, Kurban M. Scabies in the age of increasing drug resistance. PLoS Negl Trop Dis. 2017 Nov 30;11(11):e0005920. doi: 10.1371/journal.pntd.0005920. eCollection 2017 Nov.

    PubMed 29190303
  • Karthikeyan K. Treatment of scabies: newer perspectives. Postgrad Med J. 2005 Jan;81(951):7-11. doi: 10.1136/pgmj.2003.018390.

    PubMed 15640423
  • Avila-Romay A, Alvarez-Franco M, Ruiz-Maldonado R. Therapeutic efficacy, secondary effects, and patient acceptability of 10% sulfur in either pork fat or cold cream for the treatment of scabies. Pediatr Dermatol. 1991 Mar;8(1):64-6. doi: 10.1111/j.1525-1470.1991.tb00844.x.

    PubMed 1862029
  • Chosidow O. Scabies and pediculosis. Lancet. 2000 Mar 4;355(9206):819-26. doi: 10.1016/s0140-6736(99)09458-1.

    PubMed 10711939
  • Rosumeck S, Nast A, Dressler C. Ivermectin and permethrin for treating scabies. Cochrane Database Syst Rev. 2018 Apr 2;4(4):CD012994. doi: 10.1002/14651858.CD012994.

    PubMed 29608022
  • Engelman D, Yoshizumi J, Hay RJ, Osti M, Micali G, Norton S, Walton S, Boralevi F, Bernigaud C, Bowen AC, Chang AY, Chosidow O, Estrada-Chavez G, Feldmeier H, Ishii N, Lacarrubba F, Mahe A, Maurer T, Mahdi MMA, Murdoch ME, Pariser D, Nair PA, Rehmus W, Romani L, Tilakaratne D, Tuicakau M, Walker SL, Wanat KA, Whitfeld MJ, Yotsu RR, Steer AC, Fuller LC. The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies. Br J Dermatol. 2020 Nov;183(5):808-820. doi: 10.1111/bjd.18943. Epub 2020 Mar 29.

    PubMed 32034956
  • Sharma R, Singal A. Topical permethrin and oral ivermectin in the management of scabies: a prospective, randomized, double blind, controlled study. Indian J Dermatol Venereol Leprol. 2011 Sep-Oct;77(5):581-6. doi: 10.4103/0378-6323.84063.

    PubMed 21860157

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Permethrin Solution and Sulfur in people with Scabies, run by Damascus University at 3 sites in Syria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Syria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical Recovery (time frame: At day 14 and 28 following the intervention.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06396507, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in